New combo therapy targets tough cancers
Disease control
Recruiting now
This study tests a new drug called BOLD-100 combined with standard FOLFOX chemotherapy in people with advanced colorectal, pancreatic, stomach, or bile duct cancers that have spread or cannot be removed. The goal is to see if the combination is safe and helps control tumor growth…
Phase: PHASE1, PHASE2 • Sponsor: Bold Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC